Valuation: Impax Laboratories Inc

Market Cap 551.59Cr 482.97Cr 445.87Cr 416.36Cr 783.77Cr 52TCr 801.63Cr 5.37TCr 2.07TCr 26TCr 2.07TCr 2.03TCr 89TCr P/E 2026 *
50.5x
P/E 2027 * 21.3x
Enterprise Value 779.79Cr 682.79Cr 630.33Cr 588.61Cr 1.11TCr 74TCr 1.13TCr 7.59TCr 2.93TCr 36TCr 2.93TCr 2.86TCr 1,26300Cr EV / Sales 2026 *
2.51x
EV / Sales 2027 * 2.2x
Free-Float
52.02%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 01/08/2019
Chief Executive Officer 54 01/08/2019
Director of Finance/CFO 58 07/11/2023
Director TitleAgeSince
Director/Board Member 59 07/11/2023
Director/Board Member 70 07/11/2023
Director/Board Member 52 07/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
-2.00%-2.92% - - 549.68Cr
+1.81%+11.60%+58.61%+164.79% 1,07700Cr
+1.51%+11.77%+69.61%+57.53% 61TCr
+0.38%+10.56%+39.49%+90.88% 45TCr
+0.99%+5.24%+28.17%+22.73% 33TCr
-0.14%+7.58%+39.85%+27.25% 29TCr
-0.06%+4.92%+31.21%+41.59% 29TCr
-0.96%+4.98%-28.02%-40.96% 21TCr
+0.62%+4.59%+30.10%+63.03% 19TCr
-1.21%+1.17%+14.15%+66.20% 16TCr
Average -0.06%+6.86%+31.46%+54.78% 40.18TCr
Weighted average by Cap. +0.65%+8.75%+43.00%+81.53%

Financials

2026 *2027 *
Net sales 310.61Cr 271.97Cr 251.08Cr 234.46Cr 441.36Cr 29TCr 451.41Cr 3.02TCr 1.17TCr 14TCr 1.17TCr 1.14TCr 50TCr 332.95Cr 291.53Cr 269.14Cr 251.32Cr 473.1Cr 31TCr 483.88Cr 3.24TCr 1.25TCr 16TCr 1.25TCr 1.22TCr 54TCr
Net income 11Cr 9.87Cr 9.11Cr 8.51Cr 16Cr 1.07TCr 16Cr 109.62Cr 42Cr 525.6Cr 42Cr 41Cr 1.82TCr 27Cr 24Cr 22Cr 20Cr 38Cr 2.55TCr 39Cr 262.26Cr 101.25Cr 1.26TCr 101.25Cr 99Cr 4.37TCr
Net Debt 228.2Cr 199.81Cr 184.46Cr 172.25Cr 324.26Cr 22TCr 331.64Cr 2.22TCr 856.94Cr 11TCr 856.98Cr 838.18Cr 37TCr 179.83Cr 157.46Cr 145.36Cr 135.74Cr 255.52Cr 17TCr 261.35Cr 1.75TCr 675.29Cr 8.39TCr 675.33Cr 660.51Cr 29TCr
Logo Impax Laboratories Inc
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-